ALK

For more than 100 years, ALK has been at the forefront of allergy solutions. We are now stepping into the next 100 years with a mission to help even more people

[ALK @ALK_net]

#PRESS: Today at 5.00 p.m. CEST, we’ll host a webcast conference call regarding ALK’s Q1 financial results for 2026. Here’s how to join the webcast: https://t.co/s7sn2uMOtW #dkmedier #dkpharmanews #dkpharma #dkbiz #Q1results #interimreport #Q1report

[ALK @ALK_net]

#PRESS: As we've just announced our Q1 results ahead of plans, we'll host the webcast today, 4 May, at 5:00 p.m. CEST. Learn how to join us: https://t.co/s7sn2uMOtW #dkmedier #pharmanews #dkpharma #Q1report #intertimreport #Q1results

[ALK @ALK_net]

#PRESS: On Tuesday, 5 May, we’ll announce our Q1 2026 financial results. At 1:30 p.m. CEST, a webcast conference call for investors and analysts will take place. Here’s how to join: https://t.co/s7sn2uMOtW #dkmedier #pharmanews #dkpharma #dkbiz #Q1report #interimreport #Q1results

[ALK @ALK_net]

#PRESS: Our Q1 results are out w. an outlook upgrade. Our CEO says: “With continued double-digit growth we reinforce our commitment to help people with allergy as well as our leadership in the specialty allergy field” https://t.co/ozfK1dALnx #dkmedier #pharmanews #dkbiz #dkpharma

[ALK @ALK_net]

#PRESS: On Tuesday, 5 May, we’ll announce our Q1 2026 financial results. At 1:30 p.m. CEST, a webcast conference call for investors and analysts will take place. Here’s how to join: https://t.co/s7sn2uMOtW #dkmedier #pharmanews #dkpharma #dkbiz #Q1report #interimreport #Q1results

[ALK @ALK_net]

#PRESS: We just announced positive topline results from our phase 2 clinical trial within #peanutallergy, demonstrating early onset of efficacy with an investigational tablet for the treatment of patients, 4-65 years. https://t.co/oI2NvWFE29 #pharmanews #dkmedier #dkbiz #dkpharma

[ALK @ALK_net]

#PRESS: We’re excited to announce that Health Canada has approved our nasal adrenaline spray as the first needle-free anaphylaxis treatment of adults and children (>30 kg) in Canada. https://t.co/5IUaLCoazX #pharmanews #anaphylaxis #allergy #dkbiz #dkmedier #dkpharma

[ALK @ALK_net]

#PRESS: We've just released new data that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis. Read the announcement: https://t.co/jxdxULT8CL #pharmanews #dkmedier #dkpharma #dkbiz #anaphylaxis #allergy #science

[ALK @ALK_net]

#PRESS: Today at 1.30 p.m. CET, we’ll host a webcast conference call regarding ALK’s full year financial figures for 2025. Join the webcast here: https://t.co/gFF1LG7GTJ #dkmedier #pharmanews #dkpharma #dkbiz #annualreport #FYresults

[ALK @ALK_net]

#PRESS: We’ve announced changes to our Executive Leadership Team, meaning that Henriette Mersebach will be leaving ALK as per mutual agreement with our CEO and Board. Find the announcement on our website: https://t.co/v7tRxVetQo #dkmedier #pharmanews #dkbiz #dkpharma

[ALK @ALK_net]

#PRESS: Our FY & sustainability results are out. Our CEO says: “2025 was a landmark year for ALK, proving the strength of Allergy+ and reflecting our commitment to helping more people across age groups & markets.” https://t.co/lJJ1E6Ttyr #dkmedier #pharmanews #dkbiz #dkpharma

[ALK @ALK_net]

#PRESS: On Friday, 20 Feb, we’ll release our 2025 annual report, incl. our sustainability statement. At 1:30 pm CET, a webcast conference call for investors and analysts will take place. Here’s how to join: https://t.co/gFF1LG7GTJ #dkmedier #pharmanews #dkpharma #dkbiz #FYreport

[ALK @ALK_net]

#Press: We’ve received positive recommendation by the CHMP of EMA for our nasal adrenaline spray, 1mg, for the emergency treatment of allergic reactions (anaphylaxis) in children aged 4 years and older (15-30 kg): https://t.co/HirGDxnqxA. #pharmanews #dkbiz #dkpharma #dkmedier

[ALK @ALK_net]

It’s #WorldAnaphylaxisDay. Let’s spread awareness of the potentially fatal allergic disease affecting both body & mind. Quick treatment is crucial: In case of signs like facial swelling or trouble breathing, call emergency services and administer adrenaline if available. @EAACI

[ALK @ALK_net]

#PRESS: Today at 1.30 p.m. CET, we will host a webcast conference call regarding our Q3 financial results. Join it via our website here: https://t.co/TstJCbSCi8 #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

[ALK @ALK_net]

#PRESS: Our Q3 results are out. Our CEO says: “We saw continued positive momentum in the execution of key strategic growth initiatives, most notably in reaching more children with allergy, which is currently ahead of plan." https://t.co/HyfsKDL6ZL #dkmedier #pharmanews #dkpharma

[ALK @ALK_net]

#PRESS: On Thursday, 13 November, we will release our Q3 financial results for 2025. A webcast conference call for investors and analysts will take place at 1:30 p.m. CET. Here’s how to join the call: https://t.co/LztZywDx2l #dkmedier #pharmanews #dkpharma #dkbiz #intertimreport

[ALK @ALK_net]

Imagine if your child had to miss out on their best friend’s birthday party or a fun family picnic – all because of #allergy. We’re at #PAAM2025 to focus on the importance of advancing care for children worldwide. Thank you @EAACI_HQ for organising the event. #pharmanews

[ALK @ALK_net]

#PRESS: ALK & Gensci partner to expand the AIT market in China. Our CEO says: “We’re very excited about the partnership and look forward to co-operating with GenSci to benefit people with allergy in China.” Read more: https://t.co/C7r6YTRle6 #pharmanews #dkpharma #dkmedier #dkbiz

[ALK @ALK_net]

We’re at #GAFA2025 to shed an important light on #foodallergy & #anaphylaxis. Join our symposium today at 13:15 (CEST) on our latest insights and experiences in the treatment of anaphylaxis. Thank you to @GA2LEN_ANACARE for arranging the event. #allergy #science #pharmanews

[ALK @ALK_net]

#PRESS: Real-world evidence supporting clinical effectiveness of nasal adrenaline sprays in US patients experiencing anaphylaxis symptoms during oral food challenge & AIT has been accepted for scientific publication: https://t.co/9oQfQTXtbw #dkpharma #dkmedier #dkbiz #pharmanews